Novartis has tried to get its marketing application for high cholesterol therapy inclisiran in the US back on track, after the FDA rejected it last year, by changing the factory that makes the drug.

Novartis and NHS England have forged a pact to accelerate the access of its new cholesterol-lowering drug inclisiran for primary prevention of cardiovascular disease. Health Secretary Matt Hancock ...

At 1 year, two-thirds of patients treated with inclisiran (Leqvio; Novartis) on top of statin and nonstatin lipid-lowering therapies achieved an LDL target of less than 70 mg/dL compared with just ...

Provident Financial Services, Inc. operates as the bank holding company for Provident Bank that provides various banking products and services to individuals, families, and businesses in the ...

Inclisiran is a new and potent lipid-lowering drug that is shown to be effective in reducing LDL-c in randomised controlled trials, however, real-world data of its use are not yet known. We sought to ...

1 Day PFS -2.95% DJIA -1.79% S&P Mid Cap 400 -1.58% Financial Services -1.71% ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The median progression-free survival was 20.6 months in the dostarlimab-niraparib-chemotherapy arm and 19.2 months in the niraparib-chemotherapy arm. Adding dostarlimab to platinum-based ...